The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP.
The primary bile acid receptor farnesoid X receptor (FXR) maintains lipid and glucose homeostasis by regulating expression of numerous bile acid-responsive genes, including an orphan nuclear receptor and metabolic regulator SHP. Using SHP as a model gene, we studied how FXR activity is regulated by p300 acetylase. FXR interaction with p300 and their recruitment to the SHP promoter and acetylated histone levels at the promoter were increased by FXR agonists in mouse liver and HepG2 cells. In contrast, p300 recruitment and acetylated histones at the promoter were not detected in FXR-null mice. p300 directly interacted with and acetylated FXR in vitro. Overexpression of p300 wild type increased, whereas a catalytically inactive p300 mutant decreased, acetylated FXR levels and FXR transactivation in cells. While similar results were observed with a related acetylase, CBP, GCN5 did not enhance FXR transactivation, and its recruitment to the promoter was not increased by FXR agonists, suggesting functional specificity of acetylases in FXR signaling. Down-regulation of p300 by siRNA decreased acetylated FXR and acetylated histone levels, and occupancy of FXR at the promoter, resulting in substantial inhibition of SHP expression. These results indicate that p300 acts as a critical coactivator of FXR induction of SHP by acetylating histones at the promoter and FXR itself. Surprisingly, p300 down-regulation altered expression of other metabolic FXR target genes involved in lipoprotein and glucose metabolism, such that beneficial lipid and glucose profiles would be expected. These unexpected findings suggest that inhibition of hepatic p300 activity may be beneficial for treating metabolic diseases.
Department of Molecular and Integrative Physiology, University of Illinois, Urbana, Illinois 61801, USA.
Sungsoon
S
Fang
Stephanie
S
Tsang
Ryan
R
Jones
Bhaskar
B
Ponugoti
Hyeryoung
H
Yoon
Shwu-Yuan
SY
Wu
Cheng-Ming
CM
Chiang
Timothy M
TM
Willson
Jongsook Kim
JK
Kemper
D000256:Adenoviridae / Q000378:metabolism; D000818:Animals; D019826:Cholic Acid / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D006657:Histones / Q000737:chemistry; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008954:Models, Biological; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*; D015533:Transcriptional Activation; D050880:p300-CBP Transcription Factors / Q000378:metabolism / Q000502:physiology*; D000099150:Receptor, Farnesoid X-Activated; D000099224:p300-CBP-Associated Factor
D019826:Cholic Acid; D004268:DNA-Binding Proteins; D005947:Glucose; D006657:Histones; D008074:Lipoproteins; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D050880:p300-CBP Transcription Factors; D000099150:Receptor, Farnesoid X-Activated; D000099224:p300-CBP-Associated Factor; C099713:nuclear receptor subfamily 0, group B, member 2